Qiming Headlines | Connecting world-class science with top investors, the second call for startup proposals for the 1st S2S China Symposium is underway.
The first S2S (Science2Startup) China Symposium, co-hosted by the world's top venture capital firm RA Capital Management and Qiming Venture Partners, will be grandly held in Hangzhou, Zhejiang on October 15, 2026. As a top-tier entrepreneurship event in the biotech field, recently, the second round of the call for entrepreneurship proposals from top Chinese universities and research institutions for the first S2S China Symposium (https://www.s2schina.com/) is in the countdown (Deadline: April 30, 2026). ATLATL Dart Accelerator serves as the preferred partner, and Arterynet, Yiyaojie·Pharmaceutical Innovation, and Pharmcube are the strategic media partners, which will fully support the successful hosting of this S2S Symposium in China.
S2S (Science2Startup) is a globally renowned life science startup incubation platform. It originated in 2018 and was jointly founded by F-Prime Capital, SV Health, and Atlas Venture. It has now developed into the core engine of global biotech innovation. S2S China is jointly initiated by RA Capital Management and Qiming Venture Partners. RA Capital Management is one of the most active asset management companies in the global life science and healthcare fields. Qiming Venture Partners has a forward - looking and leading investment in the medical innovation field and has consistently ranked within the top 5 globally. The two powerhouses join hands to accelerate the commercialization and globalization process of China's biopharmaceutical technology through the S2S platform.
The S2S Symposium is a platform for showcasing the research results of selected scientists. It is an invitation - only symposium where top scientists can present their entrepreneurial ideas and communicate with top biotech investors.
After successfully incubating more than 14 startups and successfully hosting the S2S Japan Symposium in 2024, S2S has officially set its sights on the Chinese scientific community. The first S2S China Symposium aims to build a bridge between China's world - class scientific research achievements and the world's top biopharmaceutical capital. It is committed to unleashing the life science potential of China's academic community and providing a stage for early - stage research projects that have not received Series A financing or even established legal entities.
For this proposal solicitation, S2S China hopes to find breakthrough technologies in the proof - of - concept stage. Ideal candidate projects should have the following characteristics: - Novel proprietary academic technologies in the treatment field - Less than 4 - 5 years away from clinical application with key data support - Significantly superior to existing therapies (e.g., better meeting unmet clinical needs)
Different from ordinary roadshows, S2S uses a unique "mentorship" model to connect selected scientists with venture capital mentors. The two sides will cooperate one - on - one to refine entrepreneurial ideas and presentation materials in terms of novelty, treatment potential, and commercialization paths; Selected scientists will have the opportunity to directly communicate with top global investment institutions and industry executives to explore potential investment opportunities. These top investment institutions include RA Capital, Qiming Venture Partners, F - Prime, Atlas Venture, Foresite Capital, Lilly Asia Ventures, and Hillhouse. Selected scientists not only have the opportunity to obtain potential investment but also have the chance to establish cross - border cooperation relationships. In addition, S2S China will provide travel subsidies for finalists to ensure the unobstructed presentation of ideas. This is a rare opportunity to access the world's top investment network. We sincerely invite top scientists to visit the S2SChina official website immediately to submit proposals and embark on the accelerated journey from the laboratory to entrepreneurship. See you in Hangzhou on October 15, 2026!